Dihydroergotoxin Mesylate en es it fr

Dihydroergotoxin Mesylate Brand names, Dihydroergotoxin Mesylate Analogs

Dihydroergotoxin Mesylate Brand Names Mixture

  • No information avaliable

Dihydroergotoxin Mesylate Chemical_Formula

C33H45N5O5

Dihydroergotoxin Mesylate RX_link

No information avaliable

Dihydroergotoxin Mesylate fda sheet

Dihydroergotoxin Mesylate msds (material safety sheet)

Dihydroergotoxin Mesylate Synthesis Reference

No information avaliable

Dihydroergotoxin Mesylate Molecular Weight

591.741 g/mol

Dihydroergotoxin Mesylate Melting Point

No information avaliable

Dihydroergotoxin Mesylate H2O Solubility

No information avaliable

Dihydroergotoxin Mesylate State

Solid

Dihydroergotoxin Mesylate LogP

2.615

Dihydroergotoxin Mesylate Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Dihydroergotoxin Mesylate Indication

For use as an adjunct therapy for patients with dementia

Dihydroergotoxin Mesylate Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Dihydroergotoxin Mesylate Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Dihydroergotoxin Mesylate side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Dihydroergotoxin Mesylate Patient Information

No information avaliable

Dihydroergotoxin Mesylate Organisms Affected

Humans and other mammals